A5034329124- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Respiratory viral infections research
- Neonatal Respiratory Health Research
- Congenital Diaphragmatic Hernia Studies
- Chronic Lymphocytic Leukemia Research
- Integrated Circuits and Semiconductor Failure Analysis
- Pediatric health and respiratory diseases
- Infant Health and Development
- Healthcare Policy and Management
- Bone health and osteoporosis research
- Child and Adolescent Psychosocial and Emotional Development
- Biosimilars and Bioanalytical Methods
- Hip and Femur Fractures
- Health Systems, Economic Evaluations, Quality of Life
- Biomedical Ethics and Regulation
- Acute Lymphoblastic Leukemia research
- Rheumatoid Arthritis Research and Therapies
- Medication Adherence and Compliance
- Spondyloarthritis Studies and Treatments
- Advancements in Semiconductor Devices and Circuit Design
- Hemoglobinopathies and Related Disorders
- Child and Adolescent Health
- Pharmacological Effects and Toxicity Studies
- Viral-associated cancers and disorders
Outcomes Research Consortium
2014-2024
Health Economics and Outcomes Research (United Kingdom)
2011-2024
University Hospitals Bristol NHS Foundation Trust
2023
University Hospitals Bristol and Weston NHS Foundation Trust
2023
Ibero American University
2018-2022
Kite (United States)
2022
St. Vincent's University Hospital
2021
Trinity College Dublin
2021
The University of Texas MD Anderson Cancer Center
2017
Partnership for Health Analytic Research
2006
Infection with respiratory syncytial virus (RSV), which causes lower tract infections, is the leading cause of hospitalization among children <1 year old in United States. Risk factors for RSV include premature birth and younger chronologic age, along several comorbid conditions. However, terms costs, infants are rarely studied separately from full-term infants. The objective this study to describe cost severity hospitalizations preterm without chronic lung disease or other high-risk...
ABSTRACT The purpose of this work was to evaluate systemic glucocorticoid exposure and fracture among patients with newly-diagnosed inflammatory immune-modulated conditions. Using administrative data, inception cohorts rheumatoid arthritis (RA), asthma/chronic obstructive pulmonary disease (COPD), bowel (IBD), multiple sclerosis (MS), lupus, sarcoidosis age 18 64 years benefits coverage ≥12 months before diagnosis (January 1, 2005 December 31, 2012) were followed clinical fracture, cancer...
Background Survivors of myocardial infarction (MI) or ischemic stroke (IS) are at high risk for subsequent cardiovascular events. Hypothesis Older patients with prior MI IS recurrent events, and comorbidities such as diabetes may increase this risk. Methods Two cohorts were studied in a retrospective Medicare 20% random sample—a 2008 cohort up to 6 years follow‐up (MI, N = 26 460; IS, 17 566) 2012 1 year 548; 728). Results In older who survived an event (2012 cohort), 7.2% had 6.7% the first...
Objective This article aims to compare respiratory syncytial virus (RSV) immunoprophylaxis (IP) use and RSV hospitalization rates (RSVH) in preterm full-term infants without chronic lung disease of prematurity or congenital heart before after the recommendation against IP born at 29 34 weeks' gestational age (wGA). Study Design Infants commercial Medicaid claims databases were followed from birth through first year assess RSVH, as a function infant's wGA. was based on pharmacy outpatient...
Summary Mantle cell lymphoma (MCL) after relapse is associated with poor prognosis. No standard of care exists and available evidence for treatments limited, particularly in patients who fail Bruton tyrosine kinase inhibitor (BTKi) therapy. This multicentre retrospective chart review study, SCHOLAR‐2, addresses this knowledge gap reports on data collected from 240 relapsed/refractory MCL Europe were treated BTKi‐based therapy between July 2012 2018, had experienced disease progression while...
The SCHOLAR-5 study examines treatment patterns and outcomes of real-world follicular lymphoma (FL) patients on 3rd line (LoT) or higher, for whom existing data are limited. is a retrospective cohort using from adults (≥ 18 years) with grade 1-3a FL, initiating ≥3rd LoT after June 2014 at major centers in the US Europe. Objective response rate (ORR), complete (CR), progression-free survival (PFS) overall (OS) were analyzed by LoT. Time-to-event assessed Kaplan-Meier methods. Of 128 patients,...
Objective The objective of this study was to compare risk for respiratory syncytial virus (RSV) hospitalizations (RSVH) preterm infants 29 34 weeks gestational age (wGA) versus term before and after 2014 guidance changes immunoprophylaxis (IP), using data from the 2012 2016 RSV seasons. Study Design Using commercial Medicaid claims databases, born between July 1, 2011 June 30, were categorized as or term. RSVH during season (November–March) identified aged <6 months rate ratios (RRs)...
Aims: To examine healthcare resource utilization (HRU) and costs within 12 months after hospitalization for respiratory syncytial virus (RSVH) or unspecified bronchiolitis (UBH) in infants.Materials methods: Infants born July 1, 2009–June 30, 2015 were identified the MarketScan Medicaid Commercial databases assigned to one of three cohorts: RSVH (with/without UBH), UBH, comparator (no UBH). Each infant was as pre-term (5 groups) term (2 based on weeks gestational age (wGA). Index dates first...
Background In the ZUMA-5 trial (Clinical trials identification: NCT03105336), axicabtagene ciloleucel (axi-cel; a chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients and clear superiority relative to SCHOLAR-5 external control cohort. We update this comparison using 24-month data.Research design methods The cohort is comprised r/r FL who initiated ≥3rd line therapy after July 2014 meeting...
To assess the appropriateness of prescription medication use based upon widely accepted treatment guidelines.We analyzed administrative claims for period October 1, 1998, through September 20, 1999, supplied by 3 California health plans to determine patterns outpatient prescriptions. We compared these those expected in presence adherence guidelines.During study period, only 27.5% antidepressant users received recommended 6 months continuous therapy, 49.0% diagnosed asthma patients at least...
Infection with respiratory syncytial virus (RSV) is common among young children insured through Medicaid in the United States. Complete and timely dosing palivizumab associated lower risk of RSV-related hospitalizations, but up to 60% infants who receive population do not full prophylaxis. The purpose this study was evaluate association partial prophylaxis RSV hospitalization high-risk Medicaid-insured infants.Claims data from 12 states during 6 seasons (October 1st April 30th first year...
The objective of this study is to estimate the cost-effectiveness KTE-X19 versus standard care (SoC) in treatment relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients from a US healthcare perspective.A three-state partitioned-survival model (pre-progression, post-progression, and death) with cycle length 1 month was used extrapolate progression-free overall survival (OS) over lifetime horizon. Due long tail OS curve, modeled applying mixture-cure methodology, using assumption that...
Cost-effectiveness data on chimeric antigen receptor (CAR) T cell therapies for relapsed/refractory large B lymphoma (R/R LBCL), accounting inpatient/outpatient site of care (site), are sparse. This payer model compares lifetime costs/benefits CAR cell-treated (axicabtagene ciloleucel [axi-cel], lisocabtagene maraleucel [liso-cel], tisagenlecleucel [tisa-cel]) patients with R/R LBCL in the USA. Three-month post-infusion costs were derived from unit and real-world all-payer (RW) site-specific...
Patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) often require multiple lines of treatment and have a poor prognosis, particularly after failing covalent Bruton tyrosine kinase inhibitor (cBTKi) therapy. Newer treatments such as brexucabtagene autoleucel (brexu-cel, chimeric antigen receptor T therapy) pirtobrutinib (non-covalent BTKi) show promise in improving outcomes.